Latest Period
Q4 2025
Security Snapshot
Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) Institutional Ownership
CUSIP: 71722W107
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
172
Shares (Excl. Options)
61,960,208
Price
$16.59
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- PHAT on Nasdaq
- Shares outstanding
- 78,837,943
- Price per share
- $12.67
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 61,960,208
- Total reported value
- $1,025,500,726
- % of total 13F portfolios
- 0%
- Share change
- -469,210
- Value change
- -$3,898,720
- Number of holders
- 172
- Price from insider filings
- $12.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 71722W107.
- 172 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 172 to 56 between Q4 2025 and Q1 2026.
- Reported value moved from $1,025,500,726 to $196,438,501.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 172 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 71722W107?
CUSIP 71722W107 identifies PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 71722W107:
Significant Owners of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 8.6% | 0% | $70,447,299 | 5,985,327 | 0% | James N. Topper | 01 Nov 2025 | |
| MILLENNIUM MANAGEMENT LLC | 5.3% | +87% | $51,101,967 | +$25,636,905 | 4,178,411 | +101% | Millennium Management LLC | 06 Mar 2026 |
| Carlyle Group Inc. | 4.9% | $30,142,485 | 3,496,808 | Carlyle Group Inc. | 28 Aug 2025 | |||
| BlackRock, Inc. | 4.6% | $14,066,607 | 3,226,286 | BlackRock, Inc. | 31 Mar 2025 | |||
| PRUDENTIAL FINANCIAL INC | 0% | -100% | $8,705 | -$24,547,397 | 2,630 | -100% | PRUDENTIAL FINANCIAL INC | 31 May 2025 |
As of 31 Dec 2025, 172 institutional investors reported holding 61,960,208 shares of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT). This represents 79% of the company’s total 78,837,943 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 16% | 12,466,489 | 0% | 5.6% | $206,819,053 |
| Medicxi Ventures Management (Jersey) Ltd | 9.5% | 7,464,572 | 0% | 15% | $123,837,249 |
| Invesco Ltd. | 5% | 3,920,446 | +1.4% | 0.01% | $65,040,200 |
| BlackRock, Inc. | 4.5% | 3,555,548 | +4.5% | 0% | $58,986,540 |
| Carlyle Group Inc. | 4.4% | 3,496,808 | 0% | 0.43% | $57,977,077 |
| VANGUARD GROUP INC | 4% | 3,177,211 | -1.2% | 0% | $52,709,931 |
| Ensign Peak Advisors, Inc | 3% | 2,352,020 | -6% | 0.07% | $39,020,012 |
| MILLENNIUM MANAGEMENT LLC | 2.6% | 2,082,180 | -59% | 0.02% | $34,543,366 |
| NEA Management Company, LLC | 2.5% | 1,960,169 | 0% | 1.7% | $32,519,204 |
| 683 Capital Management, LLC | 2.3% | 1,785,000 | -1.9% | 2.5% | $29,613,150 |
| Catalys Pacific, LLC | 1.8% | 1,429,014 | +22% | 7.6% | $23,707,342 |
| WASATCH ADVISORS LP | 1.7% | 1,331,669 | -13% | 0.13% | $22,092,389 |
| GW&K Investment Management, LLC | 1.7% | 1,306,678 | +14% | 0.19% | $21,678,000 |
| STATE STREET CORP | 1.5% | 1,149,536 | +9.1% | 0% | $19,070,802 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 1,073,434 | -1.4% | 0% | $17,811,321 |
| Propel Bio Management, LLC | 0.94% | 740,918 | +34% | 10% | $12,291,830 |
| Catalio Capital Management, LP | 0.89% | 698,996 | -38% | 2.2% | $11,596,344 |
| Divisadero Street Capital Management, LP | 0.84% | 662,312 | 0.63% | $10,987,756 | |
| MOORE CAPITAL MANAGEMENT, LP | 0.76% | 600,000 | 0% | 0.2% | $9,954,000 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.7% | 549,171 | +256% | 0.01% | $9,110,747 |
| SummitTX Capital, L.P. | 0.66% | 517,820 | +34% | 0.26% | $8,590,634 |
| StepStone Group LP | 0.54% | 422,085 | 0% | 2.9% | $4,967,940 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.5% | 397,910 | +8.7% | 0% | $6,601,327 |
| NEXT CENTURY GROWTH INVESTORS LLC | 0.5% | 393,774 | 0.45% | $6,532,710 | |
| GOLDMAN SACHS GROUP INC | 0.5% | 392,045 | +158% | 0% | $6,504,026 |
Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 17,681,281 | $196,438,501 | +$737,663 | $11.11 | 56 |
| 2025 Q4 | 61,960,208 | $1,025,500,726 | -$3,898,720 | $16.59 | 172 |
| 2025 Q3 | 62,330,243 | $733,626,032 | +$59,060,064 | $11.77 | 132 |
| 2025 Q2 | 57,415,787 | $550,618,405 | -$26,654,537 | $9.59 | 117 |
| 2025 Q1 | 64,025,009 | $401,391,744 | -$24,944,522 | $6.27 | 136 |
| 2024 Q4 | 66,610,653 | $540,837,976 | -$121,495,122 | $8.12 | 141 |
| 2024 Q3 | 72,636,064 | $1,312,668,227 | +$264,199,549 | $18.08 | 133 |
| 2024 Q2 | 58,109,780 | $598,557,394 | +$27,856,700 | $10.30 | 113 |
| 2024 Q1 | 55,378,949 | $588,085,973 | +$14,631,856 | $10.62 | 112 |
| 2023 Q4 | 54,112,686 | $503,299,407 | +$11,390,968 | $9.13 | 115 |
| 2023 Q3 | 43,760,270 | $452,721,621 | +$5,267,236 | $10.37 | 109 |
| 2023 Q2 | 42,778,866 | $612,591,768 | +$176,400,941 | $14.32 | 103 |
| 2023 Q1 | 30,786,694 | $219,689,484 | +$28,315,357 | $7.14 | 83 |
| 2022 Q4 | 28,212,747 | $316,546,824 | -$21,719,929 | $11.22 | 83 |
| 2022 Q3 | 30,185,827 | $334,342,526 | +$38,042,890 | $11.08 | 87 |
| 2022 Q2 | 27,258,631 | $230,064,222 | +$9,335,400 | $8.44 | 88 |
| 2022 Q1 | 25,654,888 | $349,117,442 | -$176,036,740 | $13.61 | 74 |
| 2021 Q4 | 28,574,214 | $561,954,045 | +$49,942,191 | $19.67 | 82 |
| 2021 Q3 | 25,543,470 | $819,833,454 | +$19,152,056 | $32.10 | 81 |
| 2021 Q2 | 24,918,954 | $843,508,479 | +$13,169,188 | $33.85 | 76 |
| 2021 Q1 | 24,475,818 | $919,193,673 | +$1,760,408 | $37.56 | 82 |
| 2020 Q4 | 24,534,138 | $815,024,391 | +$96,707,884 | $33.22 | 75 |
| 2020 Q3 | 21,632,831 | $793,536,439 | -$7,640,662 | $36.67 | 57 |
| 2020 Q2 | 21,847,152 | $718,752,879 | -$3,025,534 | $32.91 | 59 |
| 2020 Q1 | 21,949,381 | $565,607,078 | +$3,219,839 | $25.82 | 47 |
| 2019 Q4 | 21,809,755 | $677,010,000 | +$593,409,007 | $31.14 | 40 |